Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 Pharmaceutical Investing
Eloxx Pharmaceuticals Announces Uplisting to Nasdaq and Pricing of $50 Million Public Offering of Common Stock Pharmaceutical Investing
FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary Pharmaceutical Investing
Xanthic Biopharma Inc. President, Gary Galitsky and Board Member, Dr. Gunther Hintz, Advance Cannabis Opportunity In Thailand Cannabis Investing News
Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine Pharmaceutical Investing
Daré Bioscience Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform Biotech Investing
Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial Pharmaceutical Investing
Shire announces revised proposal and extension of PUSU deadline to 8 May 2018 Pharmaceutical Investing
Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone Pharmaceutical Investing
